CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new molecules that enhance natural growth hormone secretion to counteract lean mass loss in obesity treatments. It focuses on maintaining muscle and bone health in patients using specific weight loss medications.
Obesity affects 1 in 6 adults in Europe, driving demand for therapy.
Agonists of the Glucagon Like Peptide 1 Receptor (GLP1RAs) such as semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) have led to substantial weight loss in millions of patients.
However, a large fraction of lost weight is attributed to loss of lean mass: muscle and bone. A reduction in lean mass increases the risk for sarcopenia and osteoporosis loss of muscle and bone.
Our analysis of 748,667 patients using GLP1RAs has s…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
